Weight-loss giant Eli Lilly joined Moonwalk Biosciences' latest funding round, which will be used to advance the biotech's adipose tissue–directed siRNA therapy into first-in-human studies for obesity in late 2027. In addition to the US pharma, the financing saw participation from Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures. The oversubscribed $70-million series B was co-led by Alpha Wave Ventures and YK Bioventures. The round comes more than two and a half yea

Phase 2a study to evaluate PannTheraPi’s first-in-class Pannexin 1-targeting therapy in patients with drug-resistant FCD, a rare and severe form of epilepsy 8 September 2026 — PannTheraPi, a clinical-stage biopharmaceutical company developing innovative treatments for neurological diseases by selectively targeting the pannexin 1 (Panx1) channel, today announces approval by the French National Agency for the Safety of Medicines and Health Products (ANSM) of its Phase 2a clinical trial evaluating

Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million) up front to collaborate on the registration and commercialization of Gan & Lee’s GLP-1 bofanglutide. Gan & Lee will also be eligible to receive milestone payments of up to €664 million ($771 million), as well as double-digit royalties on sales, according to a release . Menarini will take over regulatory submissions and commercialization in a total of 39 countries, incl

Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. Sept. 7, 2026 -- On September 7, 2026, Shanghai, Cell Stem Cell published online clinical research from CorrectSequence Therapeutics (Correctseq) in collaboration with multiple institutions in a paper titled "Clinical base editing for β-hemoglobinopathies across different genetic backgrounds", demonstrating tha

HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence of clinical activity in secondary endpoints and exploratory analyses; full HARBOR dataset to be analyzed and appropriate development path to be determined AOC pipeline continues to advance with FDA priority review granted for delpacibart zotadirsen in DMD44 and planned FDA meeting for delpacibart braxlosiran in FSHD, based

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results. Patients with head and neck cancer who took Inhibrx Biosciences’ OX40 receptor agonist in combination with Merck’s Keytruda responded at a higher rate than those who took Keytruda alone in a Phase 2 trial, clearing the way for the biotech to access what executives estimate is a $50 billion-plus market. IN

- This trial marks the fourth Phase I peptide study for Ascletis this year. - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state in non-human primate (NHP) studies utilizing Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT). - ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for seven days in NHPs. - ASC36 subcutaneous (SQ) injection demonstrated approximately 32% and 91% greater relative b

- Oral Presentation in Session VI: Hereditary Angioedema Sept. 4, 2026 -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that updated Phase II data from its ongoing BW-20805 study for hereditary angioedema (HAE) was selected for oral presentation at the Bradykinin Symposium 2026, being held on September 3-4, 2026 in Berlin, Germany. BW-20805 has shown impressive efficacy throughout the Phase II trial and da

Pfizer has found a new home for an early-stage antibody-drug conjugate (ADC) it gained through its $43-billion takeout of Seagen — then subsequently binned — according to a US securities filing from Medicus Pharma on Wednesday. In March, the pharma terminated a Phase I trial of PF-08046031 (SGN-CD228A) in patients with melanoma and other solid tumours, citing "strategic reasons." The melanotransferrin (CD228)–targeting candidate is one of more than a half-dozen Seagen-sourced ADCs that Pfizer h

US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity. The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and Company, Gaingels, Insight Partners, Nvidia, and RA Capital Management. The company plans to use the pr